Endocarditis caused by resistant enterococcus: an overview.

Area of Science:

• Infectious Diseases
• Cardiology
• Antimicrobial Resistance

Background:

• Enterococcal infective endocarditis is a serious clinical issue, often acquired in hospitals.
• Multidrug-resistant enterococcal strains complicate treatment, necessitating alternative therapeutic approaches.
• Current first-line therapy (ampicillin and gentamicin) faces challenges due to aminoglycoside resistance, vancomycin resistance, and gentamicin toxicity.

Purpose of the Study:

• To address the lack of established optimal regimens for enterococcal endocarditis when the standard cell wall drug and aminoglycoside combination cannot be used.
• To highlight the urgent need for improved understanding of pathogenesis, resistance mechanisms, and management strategies.
• To emphasize the exploration of both antimicrobial and nonantimicrobial approaches for effective patient management.

Main Methods:

• Review of current clinical challenges and treatment limitations for enterococcal endocarditis.
• Analysis of factors necessitating alternative therapeutic options beyond ampicillin and gentamicin.
• Identification of key areas for future research and clinical strategy development.

Main Results:

• The standard therapy of ampicillin and gentamicin is challenged by increasing antimicrobial resistance and drug toxicity.
• Limited clinical trial data exists for alternative regimens when the preferred combination is not viable.
• There is a critical need for better understanding of disease mechanisms and resistance patterns.

Conclusions:

• Optimal management strategies for enterococcal endocarditis, particularly when standard therapy fails, require further investigation.
• Both antimicrobial and nonantimicrobial interventions, including risk assessment and infection prevention, are crucial.
• Further research into pathogenesis, resistance, and clinical trials for alternative therapies is urgently needed.